Trials / Withdrawn
WithdrawnNCT03619005
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EndoCeutics Inc. · Industry
- Sex
- Female
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo Vaginal Insert | Daily administration of a placebo vaginal insert. |
| DRUG | Prasterone 6.5 mg (0.50%) Vaginal Insert | Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert. |
Timeline
- Start date
- 2018-11-13
- Primary completion
- 2019-08-15
- Completion
- 2019-12-06
- First posted
- 2018-08-07
- Last updated
- 2020-07-31
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03619005. Inclusion in this directory is not an endorsement.